logo-loader
viewTiziana Life Sciences PLC

Tiziana Life Sciences files patent application for its novel coronavirus treatment technology

Tiziana Life Sciences (LON:TILS) chairman and founder Gabriele Cerrone talks Proactive London's Andrew Scott through the company's update this morning which he describes as an important step in finding a solution to the current pandemic. It's filed a patent around the direct delivery method of Anti-Interlukin-6-Receptor Monoclonal Antibodies into the lungs using a handheld inhaler or nebuliser. Cerrone adds that the technology could also be applicable for use with other FDA approved mAbs and drugs.

Quick facts: Tiziana Life Sciences PLC

Price: 158.8 GBX

AIM:TILS
Market: AIM
Market Cap: £274.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 lower as US infections continue to rise

Headlines from the Proactive UK newsroom. The FTSE 100 headed lower in an uncertain start to the week as investors worried over the surge in US COVID-19 infections. The blue-chip index dipped 24 to 6,135. Deliveroo’s boss has warned that restaurants are 'hurting' due to the coronavirus...

2 weeks, 2 days ago

2 min read